Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellular immune response after infant Prevenar vaccination
NL-OMON32887Phase 4Active, not recruiting
- Sponsor
- Nederlands Vaccin Instituut
- Start
- Mar 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of pneumococcal 7-valent conjugate vaccine in pneumococcal disease (2 cohorts), sponsored by Nederlands Vaccin Instituut. Primary endpoint: Cellular immunogenicity. Started Mar 2009; status: active, not recruiting.
02
Drugs
pneumococcal 7-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NL-OMON32887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32887.